Under fire, Gilead says patient data part of Egypt govt plan
This article was originally published in Scrip
Executive Summary
Under attack from Médecins Sans Frontières (MSF) over an allegedly unfair "anti-diversion" policy being proposed for Sovaldi (sofosbuvir) licensees, Gilead claims bulk of MSF's concerns are centred around a government sanctioned program in Egypt which requires certain patient details.